Logo image of PTHS

PELTHOS THERAPEUTICS INC (PTHS) Stock Overview

USA - NYSEARCA:PTHS - US1711262048 - Common Stock

28.32 USD
+0.69 (+2.5%)
Last: 10/16/2025, 3:06:31 PM

PTHS Key Statistics, Chart & Performance

Key Statistics
52 Week HighN/A
52 Week LowN/A
Market Cap86.94M
Shares3.07M
Float1.11M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-12.08
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO02-16 2024-02-16
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


PTHS short term performance overview.The bars show the price performance of PTHS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 30

PTHS long term performance overview.The bars show the price performance of PTHS in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of PTHS is 28.32 USD. In the past month the price decreased by -15.48%.

PELTHOS THERAPEUTICS INC / PTHS Daily stock chart

PTHS Latest News, Press Relases and Analysis

PTHS Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.38 399.98B
AMGN AMGEN INC 13.51 158.64B
GILD GILEAD SCIENCES INC 15.19 145.91B
VRTX VERTEX PHARMACEUTICALS INC 23.97 104.12B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 62.81B
REGN REGENERON PHARMACEUTICALS 12.41 60.02B
ARGX ARGENX SE - ADR 89.7 50.89B
ONC BEONE MEDICINES LTD-ADR 5.11 34.76B
INSM INSMED INC N/A 34.45B
BNTX BIONTECH SE-ADR N/A 25.17B
NTRA NATERA INC N/A 24.82B
BIIB BIOGEN INC 8.87 20.81B

About PTHS

Company Profile

PTHS logo image Pelthos Therapeutics, Inc. engages in the provision of therapeutic products. The company is headquartered in Durham, North Carolina and currently employs 4 full-time employees. The company went IPO on 2024-02-16. The firm's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. ZELSUVMI is an FDA-designated novel drug, and a prescription medication approved for the treatment of molluscum that can be administered at home by parents, patients, and caregivers. The firm is also evaluating the path forward for its existing NaV 1.7 development programs for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks.

Company Info

PELTHOS THERAPEUTICS INC

4020 Stirrup Creek Drive, Suite 110

Durham NORTH CAROLINA US

Employees: 4

PTHS Company Website

PTHS Investor Relations

Phone: 19199082422

PELTHOS THERAPEUTICS INC / PTHS FAQ

What is the stock price of PELTHOS THERAPEUTICS INC today?

The current stock price of PTHS is 28.32 USD. The price increased by 2.5% in the last trading session.


What is the ticker symbol for PELTHOS THERAPEUTICS INC stock?

The exchange symbol of PELTHOS THERAPEUTICS INC is PTHS and it is listed on the NYSE Arca exchange.


On which exchange is PTHS stock listed?

PTHS stock is listed on the NYSE Arca exchange.


What is the price forecast or stock price prediction for PELTHOS THERAPEUTICS INC stock?

8 analysts have analysed PTHS and the average price target is 56.1 USD. This implies a price increase of 98.09% is expected in the next year compared to the current price of 28.32. Check the PELTHOS THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is PELTHOS THERAPEUTICS INC worth?

PELTHOS THERAPEUTICS INC (PTHS) has a market capitalization of 86.94M USD. This makes PTHS a Micro Cap stock.


How many employees does PELTHOS THERAPEUTICS INC have?

PELTHOS THERAPEUTICS INC (PTHS) currently has 4 employees.


Should I buy PELTHOS THERAPEUTICS INC (PTHS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does PELTHOS THERAPEUTICS INC (PTHS) stock pay dividends?

PTHS does not pay a dividend.


What is the Price/Earnings (PE) ratio of PELTHOS THERAPEUTICS INC (PTHS)?

PELTHOS THERAPEUTICS INC (PTHS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-12.08).


What is the Short Interest ratio of PELTHOS THERAPEUTICS INC (PTHS) stock?

The outstanding short interest for PELTHOS THERAPEUTICS INC (PTHS) is 0.36% of its float. Check the ownership tab for more information on the PTHS short interest.


PTHS Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to PTHS.


Chartmill TA Rating
Chartmill Setup Rating

PTHS Financial Highlights

Over the last trailing twelve months PTHS reported a non-GAAP Earnings per Share(EPS) of -12.08. The EPS decreased by -2876.09% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -1098.3%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-73.55%
Sales Q2Q%N/A
EPS 1Y (TTM)-2876.09%
Revenue 1Y (TTM)N/A

PTHS Forecast & Estimates

8 analysts have analysed PTHS and the average price target is 56.1 USD. This implies a price increase of 98.09% is expected in the next year compared to the current price of 28.32.


Analysts
Analysts85
Price Target56.1 (98.09%)
EPS Next Y-3.62%
Revenue Next YearN/A

PTHS Ownership

Ownership
Inst Owners10.36%
Ins Owners2.61%
Short Float %0.36%
Short Ratio0.31